BEPREVE was clinically proven to reduce ocular itch in severely allergic subjects exposed to ragweed and grass pollens as compared to placebo.*5
- These effects were seen as early as 15 minutes after treatment.
*Study Design: Two double-masked, randomized, placebo-controlled conjunctival allergen challenge (CAC) clinical studies in which patients were assigned to receive BEPREVE (1.5%) or placebo. Analysis used the CAC model of allergic conjunctivitis, where severe response in ocular itching is defined as grade ≥3 at baseline, with a maximum score of grade 4. The primary efficacy variable was patient-evaluated ocular itching at 3, 5, and 7 minutes post challenge. Dose applied 15 minutes prior to challenge.
†The data presented above are derived from a subanalysis of the entire study population.